Caccianiga Gianluigi, Barbarisi Antonio, Caccianiga Paolo, Lauritano Dorina, Ceraulo Saverio
Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Department of Medicine and Surgery, University of Milano-Bicocca, 20100 Monza, Italy.
Dent J (Basel). 2025 Mar 13;13(3):128. doi: 10.3390/dj13030128.
Denosumab is a human monoclonal antibody playing a central role in bone resorption. The impaired bone healing observed in patients on denosumab is linked to the drug's inhibition of osteoclast activity. Photobiomodulation (PBM) has garnered attention as a potential adjunctive therapy for managing oral complications in patients on denosumab therapy. The aim of this study is to provide a review of the literature regarding the benefits of photobiomodulation therapy in patients taking denosumab while providing a case report of a patient treated with this therapy. Key terms were used to search PubMed (MEDLINE), Scopus, and Web of Science, and at last, 25 articles were compared. Following the proposed review, a case of a patient is illustrated. Based on our literature findings, there are no papers regarding the benefits of photobiomodulation therapy in patients taking denosumab specifically, but there are articles regarding photobiomodulation therapy and MRONJ osteonecrosis patients, which can be caused by denosumab. Despite all the limitations of the data in the literature, it can be deduced that there are evident benefits of photobiomodulation therapy in patients taking denosumab. The integration of laser-assisted techniques and photobiomodulation into MRONJ management protocols represents a significant evolution in treatment strategies. Further studies are needed to better understand a potential association between odontoclasts (which can cause external root resorption) and neoplastic disease or medication, as well as to explore the role of photobiomodulation in the therapeutic rehabilitation process.
地诺单抗是一种在骨吸收中起核心作用的人源单克隆抗体。接受地诺单抗治疗的患者中观察到的骨愈合受损与该药物对破骨细胞活性的抑制有关。光生物调节(PBM)作为一种潜在的辅助治疗方法,用于管理接受地诺单抗治疗患者的口腔并发症,已受到关注。本研究的目的是回顾关于光生物调节疗法对接受地诺单抗治疗患者的益处的文献,并提供一例接受该疗法治疗患者的病例报告。使用关键词检索了PubMed(MEDLINE)、Scopus和科学网,最后比较了25篇文章。在进行拟议的综述之后,展示了一例患者的病例。根据我们的文献研究结果,专门关于光生物调节疗法对接受地诺单抗治疗患者益处的论文并不存在,但有关于光生物调节疗法和可能由地诺单抗引起的下颌骨坏死性骨炎(MRONJ)患者的文章。尽管文献中的数据存在所有局限性,但可以推断光生物调节疗法对接受地诺单抗治疗的患者有明显益处。将激光辅助技术和光生物调节纳入MRONJ管理方案代表了治疗策略的重大进展。需要进一步研究,以更好地理解破牙细胞(可导致牙根外部吸收)与肿瘤疾病或药物之间的潜在关联,以及探索光生物调节在治疗康复过程中的作用。